Grant: CIHR Fellowship
McMaster University
$135,000.00
Novel Plasma Biomarkers for Cognitive Decline in Older Adults
FY 2015-16
Summary
Dementia, the progressive loss of memory often seen in older adults, represents a significant health challenge for patients and caregivers in Canada, particularly as the population ages. Although researchers have made progress in understanding what dementia looks like in the brain, less is known about why it develops in the first place, and no effective treatments are available. However, because individuals with cardiometabolic disease (such as diabetes) are at greater risk of dementia, there is reason to believe that dementia and cardiometabolic disease share certain risk factors and biological causes in common. The goal of my proposed research project is to identify risk factors for dementia using data from the ORIGIN Trial, a long-term study of people with early diabetes. In the ORIGIN Trial, participants were followed for an average of 6 years, and their blood samples were tested for hundreds of blood markers ("biomarkers"), such as sugar/glucose and cholesterol levels, and thousands of genetic changes ("variants") in their DNA. Some participants experienced memory loss over the course of the study, while others did not. Using advanced statistical methods, I will investigate the relationship between the biomarkers, genetic variants, and risk of memory loss over time. While genetic testing can be complex, expensive, and difficult to access, biomarker testing is typically inexpensive and readily available at the doctor's office. Even more importantly, an individual's genetics cannot be changed, while biomarker levels can often be modified. For this reason, I will focus on pinpointing biomarkers that are not only associated with memory loss, but appear to actually cause memory loss. If such biomarkers can be identified, then prevention or delay of dementia progression may be made possible by modifying these biomarkers through simple interventions, such as diet, exercise, and prescription medications.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
338790
Name
Carere Deanna Alexis M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Novel Plasma Biomarkers for Cognitive Decline in Older Adults
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biomarkers; Cardiometabolic Disease; Cardiovascular Disease; Cognitive Decline; Dementia; Diabetes; Genetics; Genomics; Genotyping; Mendelian Randomization
Abstract
Dementia, the progressive loss of memory often seen in older adults, represents a significant health challenge for patients and caregivers in Canada, particularly as the population ages. Although researchers have made progress in understanding what dementia looks like in the brain, less is known about why it develops in the first place, and no effective treatments are available. However, because individuals with cardiometabolic disease (such as diabetes) are at greater risk of dementia, there is reason to believe that dementia and cardiometabolic disease share certain risk factors and biological causes in common. The goal of my proposed research project is to identify risk factors for dementia using data from the ORIGIN Trial, a long-term study of people with early diabetes. In the ORIGIN Trial, participants were followed for an average of 6 years, and their blood samples were tested for hundreds of blood markers ("biomarkers"), such as sugar/glucose and cholesterol levels, and thousands of genetic changes ("variants") in their DNA. Some participants experienced memory loss over the course of the study, while others did not. Using advanced statistical methods, I will investigate the relationship between the biomarkers, genetic variants, and risk of memory loss over time. While genetic testing can be complex, expensive, and difficult to access, biomarker testing is typically inexpensive and readily available at the doctor's office. Even more importantly, an individual's genetics cannot be changed, while biomarker levels can often be modified. For this reason, I will focus on pinpointing biomarkers that are not only associated with memory loss, but appear to actually cause memory loss. If such biomarkers can be identified, then prevention or delay of dementia progression may be made possible by modifying these biomarkers through simple interventions, such as diet, exercise, and prescription medications.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Carere, Deanna Alexis M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~